The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...
Pfizer divested 7.3% remaining stake in Haleon, or approximately 662 million shares, to institutional investors and Haleon ...
Health and Me on MSN4d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
GlobalData on MSN8d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s diseaseJohnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback